FY26 PAT surges 170% to Rs 263 lakh; operating cash flow sharply negative

Pat Growth 25pctNegative Operating CashflowResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.0%Reaction day

₹6.00

prior close

₹6.06

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.3%+0.3% vs market

Pharmaceuticals peers, median of 165sector+0.2%-0.2% vs sector

On the reaction day the stock moved 0.3 pts more than Nifty Microcap 250 and 0.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.2

10m

+3.1

15m

+3.1

30m

+2.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.0-0.3+0.3+0.2-0.2

Next day

+0.0-0.1+0.1-0.3+0.3

-4.5-0.8-3.7-0.5-4.0

-6.3-2.8-3.5-1.2-5.1

+5.0-1.0+6.0-0.7+5.7

-3.2+0.4-3.6-0.1-3.1

-7.2-0.5-6.7+0.6-7.8

15d

-16.0-1.9-14.1-1.8-14.2

-17.8+0.4-18.3-0.5-17.3

-3.3+3.5-6.8+0.9-4.3

-28.7+2.0-30.7+0.4-29.1

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Dipna Pharmachem posted FY26 total income of Rs 1,291 crore, up 3.3% from Rs 1,249 crore. FY26 PAT rose 170% to Rs 263 lakh from Rs 97 lakh. Steel segment drove profit at Rs 867 lakh while Chemicals swung to a Rs 512 lakh loss. Q4 was weak with income falling sharply to Rs 20.5 crore from Rs 159 crore. EPS rose to Rs 1.00. Operating cash flow was sharply negative at Rs 1,832 lakh vs Rs 919 lakh. Auditor Devadiya and Associates issued an unmodified opinion. No deviations in preferential warrant funds use.

Likely market impact

Steel segment turnaround offset Chemicals weakness, lifting full-year profit. Weak Q4 and negative cash flow are areas to watch.